Hansbiomed

Based on innovative R&D technology, the company that creates newness never found anywhere else in the world.

HansBiomed Co., Ltd. has achieved an average annual sales growth rate of 11% over the past three years, maintaining a stable financial structure.
This growth stems from diversification of its business portfolio and the expansion of its global operations through the establishment of nine overseas subsidiaries and branches.
Furthermore, beyond its existing tissue engineering R&D, the company is initiating investment in new medical technologies related to regenerative medicine, preparing for a new challenge in advancing human health.

Growth rate

Past 3 Years CAGR

Sales

898billion KRW

26th Fiscal Year , as of September 2025

patents applied and registered

as of September 2025

employees

293

as of September 2025

Establishing Korea's first tissue bank

Acquired permission for establishing Korea's first tissue bank from the Ministry of Food and Drug Safety (MFDS) in 2005.

Although there were several companies, research institutions, and universities, at that time, studying in relation to tissue engineering such as artificial organs, we acquired the first permission for establishing a tissue bank in Korea. In particular, human tissue transplants are kept sterile and aseptic in the tissue bank. We, as a specialized company furnished with the well-managed clean rooms and professional personnel, we acquired the establishment of a tissue bank and thus contribute to domestic industry related to human tissue transplant.

Registered to The U.S. FDA

Registered to The U.S. Food and Drug Administration (FDA) in 2002

From the U.S.FDA that conducts field inspection on quality management, production facility, production lines, safety, etc. on regular basis, Biomed Co., Ltd. received

Selected as "World Top-Class Product Company

Selected as "World Top-Class Product Company" sponsored by the Ministry of Commerce, Industry and Energy in 2002 and 2010.

Hans Biomed Co.'s receiving the award (World Top-Class Product Company) implies that it was acknowledged as an excellent export-driven company, which was the first for a venture company that produces human tissue transplants.

Holds the best-facility and high-tech tissue engineering research lab

Engineering research lab
whose construction completed in June 2002.

Hans Daeduk Research Center, in which a total of 6 billion KRW was invested, was constructed on the site of 11,900m2 (a total floor area of 2,644m2 but extended to 5.950m2 now) with a research unit and production facilities. On the first floor, the products related to silicone polymers such as artificial breasts are researched and produced; the products related to skin graft and restoration on the 2nd floor, and human transplant bones on the 3rd floor. Hans Daeduk Research Lab succeeded in commercializing the technology of processing acellular dermis with human transplant tissues, which is the first success in Korea and the second in the world. It presented Hans Biomed unmatchable technological competitiveness of tissue engineering in Korea. To pull up the domestic competitiveness of the domestic tissue engineering industry up to the international level, protect the national health, and substitute imports, we do our best to distribute our products in Korea and also export them to overseas markets.

Listed on Kosdaq in first in the industry.

Listed on Kosdaq in October 2009, first in the industry.

Hans Biomed leaped into a real global company that pulled its competence one notch up by securing excellent manpower and stable investment. Especially, it has gradually been replacing foreign products with its skin and bone transplants whose technology and quality was acknowledged. However, import substitution didn't satisfy us, but we export them to South America, Asia, and the Middle, not to mention the United States and Europe.